Search

INTRODUCTION: The aim of this study was to investigate the sustained virological response (SVR) of the patients treated with new generation oral direct acting oral antiviral (DAA), the factors affecting to the treatment response, the treatment compliance of the patients and the side effects of the treatment. METHODS: We enrolled 103 patients with HCV who received DAA from three tertiary hospitals between January 2016 to May 2017. The paitents were categorized as three gorups: Paitents in group-1 received Sofosbuvir plus Ledipasvir with or without ribavirin for 12 weeks, paitents in group-2 received Sofosbuvir plus Ledipasvir with or without ribavirin for 24 weeks and patiens in group-3 received Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir for 12 weeks. HCV-RNA levels, hcv genotype, hepatic fibrosis stage, hemogram and biochemical variables were recorded. The patients were followed up every 4 weeks during the treatment, and at the 4th week, 12th week and 24th week after the end of the treatment. Compliance to the treatment and side effects were recorded. SVR4, SVR12 and SVR24 datas and factors affecting to the SVR were analysed. RESULTS: Demographic features of the patients have shown in Table-1. Side effects which could be related to DAAs were reported 15 patients in group-1, 3 patients in group-2 and 11 patients in group-3 (Table-2). There was significant difference between groups in terms of frequency of the side effects (p

INTRODUCTION: Gastrointestinal (GI) symptoms in coronavirus-19 disease (COVID-19) have been reported with great variability and without standardization. In hospitalized patients, we aimed to evaluate the prevalence of GI symptoms, factors associated with their occurrence, and variation at 1 month. METHODS: The GI-COVID-19 is a prospective, multicenter, controlled study. Patients with and without COVID-19 diagnosis were recruited at hospital admission and asked for GI symptoms at admission and after 1 month, using the validated Gastrointestinal Symptom Rating Scale questionnaire. RESULTS: The study included 2036 hospitalized patients. A total of 871 patients (575 COVID+ and 296 COVID-) were included for the primary analysis. GI symptoms occurred more frequently in patients with COVID-19 (59.7%; 343/575 patients) than in the control group (43.2%; 128/296 patients) (P < 0.001). Patients with COVID-19 complained of higher presence or intensity of nausea, diarrhea, loose stools, and urgency as compared with controls. At a 1-month follow-up, a reduction in the presence or intensity of GI symptoms was found in COVID-19 patients with GI symptoms at hospital admission. Nausea remained increased over controls. Factors significantly associated with nausea persistence in COVID-19 were female sex, high body mass index, the presence of dyspnea, and increased C-reactive protein levels. DISCUSSION: The prevalence of GI symptoms in hospitalized patients with COVID-19 is higher than previously reported. Systemic and respiratory symptoms are often associated with GI complaints. Nausea may persist after the resolution of COVID-19 infection., Fondazione Cassa di Risparmio in Bologna; Italian Ministry of Education, University and Research; Fondazione del Monte di Bologna e Ravenna [SC1-BHC-01-2019]; European Grant H2020, DISCOvERIE [SC1-BHC-01-2019]; Italian Ministry of Health [Ricerca Finalizzata GR-2018-12367062], G.B. contribution to this research was permitted in part by funding from Fondazione Cassa di Risparmio in Bologna; the ItalianMinistry of Education, University and Research; and Fondazione del Monte di Bologna e Ravenna and European Grant H2020, DISCOvERIE, SC1-BHC-01-2019. M.R.B. is a recipient of a grant from the Italian Ministry of Health (Ricerca Finalizzata GR-2018-12367062). None of the funding organizations have had any role in the design and conduct of the study; in the collection, management, and analysis of the data; or in the preparation, review, and approval of the article.